Finding May Lead to New Drugs for Urinary Infections

Feb. 21 -- FRIDAY, Feb. 20 (HealthDay News) -- Potential targets for new drugs to fight the bacteria that cause many urinary tract infections have been identified by U.S. researchers.

Two molecules called yersiniabactin and salmochelin enable E. coli to steal iron from their hosts, which makes it easier for the bacteria to survive and reproduce. Identifying the two molecules -- called siderophores -- could help lead to the development of antibiotics that target pathogenic E. coli strains without harming beneficial bacteria in the gut.

The findings appear in the Feb. 20 issue of PLoS Pathogens.

"When we treat an infection with antibiotics, it's like dropping a bomb -- nearly everything gets wiped out, regardless of whether it's helpful or harmful. We'd like to find ways to target the bad bacteria and leave the good bacteria alone, and these siderophores are a great lead in that direction," study author Jeff Henderson, of the Center for Women's Infectious Disease Research at Washington University School of Medicine in St. Louis, said in a Public Library of Science news release.

The E. coli bacteria that cause urinary tract infections might come from the human gut, where several strains of the bacteria reside. But it's believed that other strains help aid digestion and block other infectious organisms.

Related Stories

5th body recovered in Baltimore bridge collapse

• May 2, 12:19 AM

4 big takeaways from Day 10 of Trump trial

• May 2, 5:50 PM

Man kills wife, 3 kids in mass shooting: Police

• Apr 23, 12:35 PM

For their study, Henderson and his colleagues used a method called metabolomics to study the differences between disease-causing and friendly E. coli strains. Metabolomics involves analyzing all the chemicals produced by a cell, including growth signals, toxins and waste products.

"This allows us to look at the end products of many genes working together," senior study author Scott Hultgren explained in the news release. "We assess what all the various assembly lines are producing and which products disease-causing bacteria prefer to make, such as certain siderophores."

Drugs that block or disrupt the activity of the proteins that make siderophores could be one way to fight disease-causing bacteria. Another approach is what the researchers call a "Trojan horse" strategy.